United Therapeutics Corp Live Stock Price Today, Share Analysis and Chart

Name: United Therapeutics Corp: Is Infosys Ltd. worth buying?
Item: United Therapeutics Corp
Rating: 2.85615275
Author: Trendlyne DVM scores

Strong Performer, Getting Expensive

about

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on...

481.63 0.67 (0.14%)

Near 52W High of $492.62

182.5K

XNAS Volume

XNAS 04 Dec, 2025 12:07 PM (EST)

High Financial Strength

61.1 / 100

Mid Valuation

44.0 / 100

Technically Moderately Bullish

62.3 / 100

Strong Performer, Getting Expensive These stocks are strong in quality and technical aspects but with medium valuation. Due to expensive valuation it is suggested that opportunity to be observed before buying. View Similar Embed DVM

518

1Yr Price target upside is 8%

12 analysts

United Therapeutics Corp Live Price Chart

Switch to TradingView

Loading Fundamental data..

Loading data..

United Therapeutics Corp Live Stock Price Today, Share Analysis and Chart

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on...

Near 52W High of $492.62

SWOT Analysis

United Therapeutics Corp Live Price Chart